MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15Business Wire • 09/09/21
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and AsthmaBusiness Wire • 08/24/21
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative DiseasesBusiness Wire • 08/10/21
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 VaccineBusiness Wire • 08/10/21
MyMD Pharma Stock Is Trading Higher As COVID-19 Candidate Effective In Suppressing Cytokine StormBenzinga • 08/05/21
MyMD Pharmaceuticals' Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell StudyBusiness Wire • 08/05/21
MyMD Pharmaceuticals' Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and DermatitisBusiness Wire • 07/27/21
MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1Business Wire • 07/07/21
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory BoardBusiness Wire • 05/17/21
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals' Supera-CBD at the 3rd Annual Neuroimmunology Drug Development SummitBusiness Wire • 04/28/21
MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid CompoundsBusiness Wire • 04/22/21
MyMD Pharmaceuticals IPO: 10 Things for MYMD Stock Investors to Know as Shares SurgeInvestorPlace • 04/20/21
